Clinical Trial Aims to Unravel Genetic Markers of MRD in Multiple Myeloma Patients
The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center are collaborating to launch a new clinical trial studying minimal…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Excess Body Fat Increases Risk for 8 More Cancer Types, Special Report Says
The association between excess body fat and increased risk of various cancers is an undisputed fact. Now, the findings of a working group from the International…
Minimal Residual Disease in Myeloma Suggested as Clinical Trial Endpoint, but Experts Disagree
Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study…
Janssen Seeks to Expand Darzalex Use for Multiple Myeloma Patients
Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include…
In Heavily Treated Myeloma Patients, Selinexor-Dexamethasone Combo Shows Positive Results
Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results…
Survival of Younger Myeloma Patients Influenced by Marriage and Insurance, not Ethnicity, Study Finds
With advances in treatment for multiple myeloma, some studies have reported improved survival rates, especially among young white patients and, to a lesser extent, in patients…
